Literature DB >> 12362243

Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro.

Berta Fusté1, Mireia Serradell, Ginés Escolar, Aleix Cases, Roberto Mazzara, Ricardo Castillo, Antonio Ordinas, Maribel Díaz-Ricart.   

Abstract

We demonstrate that exposure of cultured human endothelial cells to rHuEPO resulted in a dose-dependent increase in the tyrosine kinase activity, with phosphorylation of JAK-2 followed by rapid phosphorylation of STAT-5. Simultaneously, rHuEPO induced long-lasting phosphorylation of MAPK p42/44. Activation of this signaling pathways was directly associated with an increase in the thrombogenic properties of the extracellular matrix generated by these cells, when they were exposed to flowing blood. The enhancement in the reactivity of the resulting extracellular matrix towards platelets was associated with a higher expression of tissue factor. All these effects were blocked by an antibody to the EPO receptor and by specific inhibitors of tyrosine phosphorylation. The observed action of rHuEPO on endothelial cells seemed to be specifically triggered by the subsequent events that follow receptor binding, and occurred even at pharmacological concentrations of the cytokine. Our results indicate that rHuEPO has a direct action on the endothelium, increasing the reactivity of the underlying extracellular matrix towards platelets, effect that may be attributed to an increase in the expression of TF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12362243

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  20 in total

Review 1.  Cardiorenal syndrome: still not a defined entity.

Authors:  Carlo Longhini; Christian Molino; Fabio Fabbian
Journal:  Clin Exp Nephrol       Date:  2010-02-20       Impact factor: 2.801

2.  Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.

Authors:  Ahmed Mohyeldin; Huasheng Lu; Clifton Dalgard; Stephen Y Lai; Noam Cohen; Geza Acs; Ajay Verma
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

3.  Erythropoietin neuroprotection with traumatic brain injury.

Authors:  Lucido L Ponce; Jovany Cruz Navarro; Osama Ahmed; Claudia S Robertson
Journal:  Pathophysiology       Date:  2012-03-14

Review 4.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

Review 5.  Erythropoietin or darbepoetin for patients with cancer.

Authors:  Thomy Tonia; Annette Mettler; Nadège Robert; Guido Schwarzer; Jerome Seidenfeld; Olaf Weingart; Chris Hyde; Andreas Engert; Julia Bohlius
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

6.  Erythropoietin in thyroid cancer.

Authors:  C M Yates; A Patel; K Oakley; A Helms; R M Tuttle; G L Francis
Journal:  J Endocrinol Invest       Date:  2006-04       Impact factor: 4.256

7.  A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury.

Authors:  Fabio Fiordaliso; Stefano Chimenti; Lidia Staszewsky; Antonio Bai; Eleonora Carlo; Ivan Cuccovillo; Mirko Doni; Manuela Mengozzi; Rossella Tonelli; Pietro Ghezzi; Thomas Coleman; Michael Brines; Anthony Cerami; Roberto Latini
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-25       Impact factor: 11.205

8.  A clinical cardiology perspective of thrombophilias.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2010-10       Impact factor: 2.300

9.  Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.

Authors:  Thomas R Coleman; Christof Westenfelder; Florian E Tögel; Ying Yang; Zhuma Hu; Leanne Swenson; Henri G D Leuvenink; Rutger J Ploeg; Livius V d'Uscio; Zvonimir S Katusic; Pietro Ghezzi; Adriana Zanetti; Kenneth Kaushansky; Norma E Fox; Anthony Cerami; Michael Brines
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

10.  Pretransplantation erythropoiesis-stimulating agent hyporesponsiveness is associated with increased kidney allograft failure and mortality.

Authors:  Nadiesda A Costa; Abhijit V Kshirsagar; Lily Wang; Randal K Detwiler; M Alan Brookhart
Journal:  Transplantation       Date:  2013-11-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.